Filtered By:
Management: Marketing

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 200 results found since Jan 2013.

Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes
Abstract Atrial fibrillation is the most common arrhythmia and is associated with significant morbidity and mortality. The current therapeutic options for patients at high thromboembolic risk include the vitamin K antagonists and the direct oral anticoagulants. These novel agents have been evaluated in more than 40,000 patients enrolled in four large randomized controlled trials for stroke prevention in non-valvular atrial fibrillation. When these results were pooled together, a greater efficacy profile, as well as a consistent reduction in life-threatening bleeding was shown in comparison to vitamin K antagonists...
Source: Internal and Emergency Medicine - July 7, 2015 Category: Emergency Medicine Source Type: research

McGuire to take reins at Second Sight, Greenberg heads board | Personnel Moves
Second Sight Medical‘s (NSDQ:EYES) newly appointed CEO Will McGuire is set to take the reins starting August 18, the company said. Announced in June, former CEO Dr. Robert Greenberg will become chairman of the board at Second Sight, replacing Alfred Mann who will become chairman emeritus, according to the Sylmar, Calif.-based ‘bionic eye’-developing company. “Will brings an immense depth of experience in the life sciences industry that will advance Second Sight’s commercialization of the Argus II retinal prosthesis. After a thorough search process, management and the board of directors are con...
Source: Mass Device - August 13, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Invuity Monteris Medical Personnel Moves Second Sight Medical Products Inc. Volcano Corp. Source Type: news

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer’s Xarelto® in Patients with Non-Valvular Atrial Fibrillation (for specialized target groups only)
Insights from more than 45,000 real-world patients with atrial fibrillation (AF) confirm low bleeding rates for Xarelto / Late-breaking XANTUS study expands on ROCKET AF data, demonstrating Xarelto provides highly effective stroke prevention in both high- and lower-risk patients / Two-year findings from an ongoing post-marketing safety surveillance (PMSS) study show rates and patterns of major bleeding to be consistent with ROCKET AF
Source: Bayer Company News - September 1, 2015 Category: Pharmaceuticals Source Type: news

South Carolina Is FED UP
When asked to speak for a group of third and fourth graders about making "healthy choices," I picked the topic that most children have in common ... sugar! I began our discussion with one simple question. "If your parents came into the room and saw you eating out of the sugar bowl, what would they say?" One young man stated it best. "Are you crazy? Put that spoon down!" "Why would your parents say that?" I asked. Another little girl could barely contain herself. Waving her hand furiously she blurted out, "Because all that sugar is bad for you!" Out of the mouths of babes. When I talk to children, teens or adults,...
Source: Healthy Living - The Huffington Post - September 17, 2015 Category: Consumer Health News Source Type: news

No, Omega 3-Enriched Beef Is Not Necessarily Heart Healthy
Feeding cattle flaxseed or marine algae can raise the omega-3 fatty acid levels in ground beef from 30 milligrams per serving to 200 milligrams per serving, as Kansas State University researchers have found. But do higher levels of omega-3s make red meat significantly healthier?   Not according to Kim Larson, a registered dietitian nutritionist and spokesperson for the Academy of Nutrition and Dietetics. The attempt to make beef look like an important source of omega-3s is essentially a marketing ploy, she said. And despite the fatty acid's reputation as a health ...
Source: Science - The Huffington Post - October 14, 2015 Category: Science Source Type: news

Silk Road Medical Announces up to $57 Million in New Funding for Novel Approach to Preventing Strokes
Financing to Support Commercialization of First-in-Class Products for TransCarotid Artery Revascularization (TCAR) Procedure SUNNYVALE, Calif., Oct. 20, 2015 -- (Healthcare Sales & Marketing Network) -- Silk Road Medical, Inc., a company dedicated to a... Devices, Interventional, Venture CapitalSilk Road Medical, Transcarotid Neuroprotection, Transcarotid Stent, stroke
Source: HSMN NewsFeed - October 20, 2015 Category: Pharmaceuticals Source Type: news

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio
Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgroup of patients that could be either over-treated, risking bleeding, or under-treated, risking embolism. Additional post-marketing data lends support to the favorable therapeutic profile of dabigatran but at the same time raises doubts about patient characteristics such as weight, age, renal function and their ...
Source: Therapeutic Advances in Neurological Disorders - October 27, 2015 Category: Neurology Authors: Safouris, A., Triantafyllou, N., Parissis, J., Tsivgoulis, G. Tags: Reviews Source Type: research

Health News: Believe it or Not
Vitamin D Deficiency May Cause MS Employees Working Long Hours Face Increased Risk of Stroke Coffee Could Literally be a Lifesaver When you see these health headlines do you immediately think of how it pertains to you or someone you know?  You probably don’t think, “I should make sure this information is from a reputable source,” or “I should read that research article that this information is based on and ask my clinician about it.” Health care reporting is complicated and has its challenges.  Many journalists do not have the background or education in health and science and are just as uni...
Source: Dragonfly - December 11, 2015 Category: Databases & Libraries Authors: Carolyn Martin Tags: Health Literacy/Consumer Health Source Type: news

This Is By Far The Best Way To Avoid Lower Back Pain
By: Cari Nierenberg Published: 01/11/2016 06:35 PM EST on LiveScience Shoe inserts, back-support belts and other gadgets aimed at preventing low back pain may be a waste of money. Instead, exercise is the best way to ward off this common problem, a new review of studies suggests. The researchers found evidence that an exercise program alone, or exercise along with education about how to prevent back pain, was effective in averting an episode of low back pain and reducing people's use of sick time at work. Education may include receiving training in proper lifting techniques, learning about correct posture or attending...
Source: Science - The Huffington Post - January 12, 2016 Category: Science Source Type: news

InspireMD CEO Milinazzo, CTO Bar to bow out | Personnel Moves
InspireMD (OTC:NSPR) said today that it’s looking for a replacement for CEO Alan Milinazzo as it looks to drill down on the largest markets for its CGuard and MGuard stents, which are designed to help prevent blood clots that can cause stroke. Milinazzo agreed to stay on until either a replacement is found or June 30, whichever comes 1st. The new CEO will be hired to grow sales in Europe and improve the balance sheet, InspireMD said. The Boston-based company said also said it tapped as vice chairman biotech legend Isaac Blech, the founder of Celgene (NSDQ:CELG), ICOS Corp., Pathogenesis, Nova Pharmaceutical and Gene...
Source: Mass Device - January 22, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Business/Financial News HemaFlo Therapeutics InspireMD Intuitive Surgical Inc. IsoRay RefleXion Medical Reva Medical Inc. Source Type: news

Brainlab invests nearly $8m into Jan Medical
Jan Medical said today it obtained $7.5 million in Series C funding from partner Brainlab Inc, with funds slated to aid in completion of a clinical trial and filing for de novo clearance with the FDA and CE Mark approval in the European Union for its BrainPulse tool. Mountain View, Calif.-based Jan Medical’s BrainPulse device is designed to non-invasively capture novel physiological signals through a patient’s cardiac output, used to measure vascular and brain tissue conditions, the company said. The data can be used as an ‘aid to diagnoses’ for multiple indications, including concussion and stro...
Source: Mass Device - January 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Diagnostics Regulatory/Compliance Brainlab Jan Medical Source Type: news

Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side‐Effect Profiles
ABSTRACT Pharmacotherapy directed toward reducing body weight may provide benefits for both curbing obesity and lowering the risk of obesity‐associated co‐morbidities. However, many weight loss medications have been withdrawn from the market due to serious adverse effects. Examples include pulmonary hypertension (aminorex), cardiovascular toxicity, e.g. flenfluramine‐induced valvopathy, stroke (phenylpropanolamine), excess non‐fatal cardiovascular events (sibutramine), and neuro‐psychiatric issues (rimonabant ‐ approved in Europe, but not in the US). This negative experience has helped mold the current drug dev...
Source: Diabetes, Obesity and Metabolism - March 1, 2016 Category: Endocrinology Authors: Andrew J. Krentz, Ken Fujioka, Marcus Hompesch Tags: REVIEW ARTICLE Source Type: research

Public Health and Citizens, Truly United
There are just two problems with the prevailing conception of "public health" -- the public, and health. Neither means what we think it means. For starters, there is no public. The public is an anonymous mass, a statistical conception, nameless, faceless, unknowable, and unlovable. I have made the case before that laboring under this crippling fiction, the potential good that all things "public health" might do is much forestalled. We talk, for instance, about the genuine potential to eliminate up to 80 percent of the total global burden of chronic disease -- heart disease, cancer, stroke, diabetes, dementia -- but somehow...
Source: Healthy Living - The Huffington Post - March 3, 2016 Category: Consumer Health News Source Type: news

Pretty Much Nobody In The U.S. Leads A Healthy Lifestyle
Only 2.7 percent of U.S. adults hit the four key metrics of living a healthy lifestyle -- abstaining from smoking, eating well, exercising and maintaining a healthy body fat percentage -- according to a disheartening new study. The study's lifestyle benchmarks for health weren't particularly high. Being smoke-free, exercising moderately and eating USDA recommended foods don't seem like particularly difficult marks to hit. So why do so many Americans fall short of living healthy lives?  "That is the million dollar question," Ellen Smit, a senior author of the study and an associate professor at the Oregon State Un...
Source: Science - The Huffington Post - March 25, 2016 Category: Science Source Type: news

Zynex Hires Vice President of Operations
LONE TREE, Colo., June 6, 2016 -- (Healthcare Sales & Marketing Network) -- Zynex (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodi... Devices, PersonnelZynex, electrotherapy, NeuroMove
Source: HSMN NewsFeed - June 6, 2016 Category: Pharmaceuticals Source Type: news